IRIS
GIORDANO, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.496
EU - Europa 1.722
AS - Asia 1.518
SA - Sud America 318
Continente sconosciuto - Info sul continente non disponibili 317
AF - Africa 28
OC - Oceania 2
Totale 6.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.401
SG - Singapore 614
IE - Irlanda 416
RU - Federazione Russa 402
CN - Cina 324
IT - Italia 260
BR - Brasile 253
HK - Hong Kong 232
SE - Svezia 174
DE - Germania 128
FR - Francia 117
VN - Vietnam 97
BD - Bangladesh 94
GB - Regno Unito 60
CA - Canada 40
UA - Ucraina 40
FI - Finlandia 32
IN - India 29
MX - Messico 27
AE - Emirati Arabi Uniti 23
NL - Olanda 23
AR - Argentina 21
ID - Indonesia 18
PL - Polonia 18
ZA - Sudafrica 14
IQ - Iraq 13
TR - Turchia 13
VE - Venezuela 12
CZ - Repubblica Ceca 11
AT - Austria 9
JP - Giappone 9
ES - Italia 8
JO - Giordania 8
EC - Ecuador 7
CL - Cile 6
CO - Colombia 6
PY - Paraguay 6
CR - Costa Rica 5
JM - Giamaica 5
LT - Lituania 5
PK - Pakistan 5
SA - Arabia Saudita 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
UZ - Uzbekistan 4
ET - Etiopia 3
KZ - Kazakistan 3
NO - Norvegia 3
NP - Nepal 3
OM - Oman 3
PH - Filippine 3
RO - Romania 3
SV - El Salvador 3
TH - Thailandia 3
UY - Uruguay 3
BE - Belgio 2
CG - Congo 2
DZ - Algeria 2
EE - Estonia 2
GT - Guatemala 2
GY - Guiana 2
KR - Corea 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BB - Barbados 1
BO - Bolivia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MQ - Martinica 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.086
Salva come PNG Salva come JPEG
Città #
San Jose 659
Dublin 415
Singapore 291
Ashburn 282
Hong Kong 232
Dallas 166
Beijing 142
Nyköping 134
Santa Clara 119
Columbus 91
Council Bluffs 88
Lauterbourg 77
New York 68
Munich 54
Moscow 43
Ho Chi Minh City 42
Princeton 36
The Dalles 36
Chandler 34
São Paulo 33
Jacksonville 28
Los Angeles 27
Frankfurt am Main 25
Phoenix 25
Hanoi 23
Helsinki 21
Seattle 20
Milan 18
Hudson 17
Rome 17
Wilmington 16
Bari 14
Brooklyn 14
Mexico City 14
North Bergen 13
Atlanta 12
Chennai 11
Warsaw 11
Düsseldorf 10
Montreal 10
Rio de Janeiro 10
Brno 9
Chicago 9
London 9
Shanghai 9
Turku 9
Washington 9
Amsterdam 8
Grosseto 8
Nuremberg 8
San Francisco 8
Boston 7
Johannesburg 7
Naples 7
Orem 7
Tokyo 7
Toronto 7
Amman 6
Belo Horizonte 6
Brasília 6
Dhaka 6
Falkenstein 6
Houston 6
Manchester 6
Andria 5
Bologna 5
Des Moines 5
Guangzhou 5
Miami 5
Palermo 5
San Antonio 5
Stockholm 5
Abbeville 4
Assago 4
Baghdad 4
Borås 4
Buffalo 4
Chengdu 4
Florence 4
Haiphong 4
Kingston 4
Las Vegas 4
Martina Franca 4
Noicattaro 4
Pescara 4
Porto Alegre 4
Potenza 4
Pune 4
São José do Rio Preto 4
Tashkent 4
Viamão 4
Addis Ababa 3
Ankara 3
Bangkok 3
Biên Hòa 3
Boardman 3
Cape Town 3
Changsha 3
Charlotte 3
Colorado Springs 3
Totale 3.711
Salva come PNG Salva come JPEG
Nome #
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 127
Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma 125
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 115
Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines 111
Centrosome linker–induced tetraploid segregation errors link rhabdoid phenotypes and lethal colorectal cancers 111
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 110
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 109
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report 108
Evidence‐based second‐line treatment in ras wild‐type/mutated metastatic colorectal cancer in the precision medicine era 104
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 103
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study 101
Aberrant BLM cytoplasmic expressionassociates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer 99
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis 97
CROC-Mutated rhabdoid colorectal carcinoma showing in intracellular spaces lamellipodia and cellular projectionts revealed by electron microscopy 97
Crosstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: Potential targets for new therapeutic approaches 97
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 95
TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation 95
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer 93
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer 93
Cancer drug related cardiotoxicity during breast cancer treatment 93
Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report 91
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 88
Morphology and molecular features of rare colorectal carcinoma histotypes 87
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 85
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 84
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables 84
Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens 83
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 83
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. 81
Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer 80
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 79
Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report 79
Solitary metastasis from renal cell carcinoma to the choroid plexus: A case illustration and review of the literature 78
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 77
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept 77
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 77
Eribulin for metastatic breast cancer (MBC) treatment: A retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) 76
Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer 76
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 73
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 73
Eribulin in male patients with breast cancer: The first report of clinical outcomes 72
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 72
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 71
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients? 70
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 69
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 69
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 68
The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs 66
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 66
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era 65
Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process 65
Metastatic melanoma: An unusual presentation 65
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1 64
Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives 63
Solitary fibrous tumor/hemangiopericytoma of the cervical spine: A systematic review of the literature with an illustrative case 63
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 63
MiRNA expression affects survival in patients with obstructive sleep apnea and metastatic colorectal cancer 62
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment 62
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 62
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes 62
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 61
Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma 60
Single-cell proteo-genomic reveals a comprehensive map of centrosome-associated spliceosome components 60
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 60
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 60
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 60
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 59
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions 58
Immune resistance and egfr antagonists in colorectal cancer 58
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models) 58
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations 56
MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer 53
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 53
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 52
Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer 52
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 51
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 49
Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate 49
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data 48
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review 47
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 45
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index 43
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 43
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study 43
Real-life second-line therapies outcome in metastatic pancreatic cancer (mPDAC) patients previously treated with gemcitabine plus nab-paclitaxel (Gem-Nab): An Italian multicenter study 34
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population 27
Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab–Bevacizumab 27
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 22
Totale 6.401
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022146 0 0 0 1 10 2 11 15 21 39 2 45
2022/2023803 80 23 47 7 35 53 7 46 433 8 48 16
2023/2024275 27 23 25 19 24 77 13 22 5 3 2 35
2024/20251.360 47 23 33 105 43 272 94 116 229 116 136 146
2025/20262.838 161 339 248 292 145 122 500 295 267 214 161 94
2026/2027814 61 237 233 283 0 0 0 0 0 0 0 0
Totale 6.401